Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanshinone IIA sulfonate sodium aerosol inhalation for pulmonary arterial hypertension
ChiCTR-IPR-15006669Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sulfo-tanshinone sodium in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: 6-minute walking test and 1-minute heart rate recovery. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
sulfo-tanshinone sodium
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on ChiCTR-IPR-15006669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006669.